Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries

Hsieh, Ruey Kuen; Chan, Alexandre; Kim, Hoon-Kyo; Yu, Shiying; Kim, Jong Gwang; Lee, Myung Ah; Dalén, Johan; Jung, Hun; Liu, Yan Ping; Burke, Thomas; Keefe, Dorothy

doi:10.1007/s00520-014-2373-2

Cited by 51 publications

(65 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1] In a recent review of the incidence of CINV, around twenty to forty percent of patients failed to respond to the current antiemetic treatments in relation to either vomiting or nausea with nausea being less well managed. [2] Nausea and delayed CINV are reported as particular challenges in clinical practice. Thus a significant impetus exists to develop more effective treatments.…”

Section: Introductionmentioning

confidence: 99%

In silico investigation into the interactions between murine 5-HT3 receptor and the principle active compounds of ginger (Zingiber officinale)

Lohning

Marx

Isenring

2016

Journal of Molecular Graphics and Modelling

View full text Add to dashboard Cite

. In silico investigation into the interactions between murine 5-HT3 receptor and the principle active compounds of ginger (Zingiber officinale).. Retrieved from http://dx.doi. org/10.1016/j.jmgm.2016.10.008 1 Abstract Gingerols and shogaols are the primary non-volatile actives within ginger (Zingiber officinale).These compounds have demonstrated in vitro to exert 5-HT3 receptor antagonism which could benefit chemotherapy-induced nausea and vomiting (CINV). The site and mechanism of action by which these compounds interact with the 5-HT3 receptor is not fully understood although research indicates they may bind to a currently unidentified allosteric binding site. Using in silico techniques, such as molecular docking and GRID analysis, we have characterized the recently available murine 5-HT3 receptor by identifying sites of strong interaction with particular functional groups at both the orthogonal (serotonin) site and a proposed allosteric binding site situated at the interface between the transmembrane region and the extracellular domain. These were assessed concurrently with the top-scoring poses of the docked ligands and included key active gingerols, shogaols and dehydroshogaols as well as competitive antagonists (e.g. setron class of pharmacologically active drugs), serotonin and its structural analogues, curcumin and capsaicin, non-competitive antagonists and decoys. Unexpectedly, we found that the ginger compounds and their structural analogs generally outscored other ligands at both sites. Our results correlated well with previous site-directed mutagenesis studies in identifying key binding site residues. We have identified new residues important for binding the ginger compounds. Overall, the results suggest that the ginger compounds and their structural analogues possess a high binding affinity to both sites. Notwithstanding the limitations of such theoretical analyses, these results suggest that the ginger compounds could act both competitively or non-competitively as has been shown for palonosetron and other modulators of CYS loop receptors. KeywordsGinger antiemetic Zingiber officinale gingerol shogaols chemotherapy induced nausea vomiting 2

show abstract

Section: Introductionmentioning

confidence: 99%

In silico investigation into the interactions between murine 5-HT3 receptor and the principle active compounds of ginger (Zingiber officinale)

Lohning

Marx

Isenring

2016

Journal of Molecular Graphics and Modelling

View full text Add to dashboard Cite

show abstract

“…The Pan Australasian Chemotherapy Induced Emesis burden of illness (PrACTICE) study evaluated the burden of CINV among patients receiving HEC or MEC in six countries across the Asia-Pacific (AP) region [14-18]. Data pertaining to the incidence of CINV in various chemotherapy cycles [14,16], the pattern of CINV prophylaxis in practice [15], predictors of anticipatory CINV [17], and the influence of CINV on modifications made to earlier cycles of chemotherapy regimens [16] have been previously published.…”

Section: Introductionmentioning

confidence: 99%

“…Data pertaining to the incidence of CINV in various chemotherapy cycles [14,16], the pattern of CINV prophylaxis in practice [15], predictors of anticipatory CINV [17], and the influence of CINV on modifications made to earlier cycles of chemotherapy regimens [16] have been previously published. The results of these studies demonstrated that CINV in prior cycles was a strong and consistent predictor of CINV in subsequent cycles, and the incidence of chemotherapy regimen modification because of CINV was low in individual cycles [16], thus highlighting the importance of preventing CINV in cycle 1 to reduce anticipatory nausea and vomiting in subsequent cycles [17].…”

Section: Introductionmentioning

confidence: 99%

Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study

Lee

Cho

et al. 2016

Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

PurposeThis study reported patient outcomes of chemotherapy-induced nausea and vomiting (CINV) prophylaxis for highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) regimens and evaluated its adherence to acute-phase CINV prophylaxis in the Korean population subset of the Pan Australasian Chemotherapy Induced Emesis burden of illness (PrACTICE) study.Materials and MethodsThis subgroup analysis evaluated 158 Korean patients receiving HEC or MEC and compared the data (wherever possible) with that of 648 patients from the Asia-Pacific (AP) region. Study endpoints included evaluation of primary CINV prophylaxis and adherence to acute-phase CINV prophylaxis in cycle 1 (American Society of Clinical Oncology [ASCO] Quality Oncology Practice Initiative [QOPI]).ResultsIn South Korea and the AP, a 5-hydroxytryptamine-3 receptor antagonist (5HT3-RA) prophylaxis for the acute phase was administered to 79/80 patients (98.8%) for HEC and 70/71 patients (98.6%) for MEC regimens (QOPI-1). Triple regimen (corticosteroid–5HT3-RA–neurokinin 1-RA) was initiated in 46/80 patients (57.5%) for prophylaxis of acute CINV in cycle 1 of HEC (QOPI-3). Double regimen (corticosteroid–5HT3-RA, with or within NK1-RA) was initiated in 61/71 patients (83.1%) for control of acute CINV in cycle 1 of MEC a(QOPI-2).ConclusionActive management of CINV is necessary in cycle 1 of HEC in South Korea, despite higher rates than the AP region. Adherence to the international guidelines for CINV prophylaxis requires attention in the acute phase in cycle 1 of the HEC regimen.

show abstract

“…The similar principle has been used in several other studies 14 17 18. In our study, score ≥3 on a 10-point Visual Analogue Scale for nausea was used as the limit value between well-controlled CINV and uncontrolled CINV, based on the study performed by Hsieh et al 14 In that study, the same score was used for defining ‘clinically significant nausea’. An additional criterion for the well-controlled group in our study was the absence of vomiting, which has not been reported in similar studies.…”

Section: Discussionmentioning

confidence: 97%

“…Data regarding antiemetic therapy post-discharge and the level of acute and delayed CINV control were obtained using translated MASCC Antiemesis Tool (MAT) questionnaire for the patients (available online in the supplementary material). 13 14 The emetogenic potential of a chemotherapy regimen was defined by the antineoplastic agent with the highest emetogenic potential in the regimen, which is in accordance with the internal Guidelines 3 12. Patients who had not vomited nor had experienced any nausea ≥level 3 (on a 10-point Visual Analogue Scale marked on the MAT questionnaire) were defined as patients with ‘controlled CINV’, whereas patients who had vomited or had experienced nausea ≥level 3 at least once were defined as ‘uncontrolled CINV’.…”

Section: Methodsmentioning

confidence: 99%

Control of chemotherapy-induced nausea and vomiting in patients with gastrointestinal tumours

2016

View full text Add to dashboard Cite

ObjectivesDuring cancer treatment, many patients experience chemotherapy-induced nausea and vomiting (CINV), which leads to a lower quality of life and poorer adherence to the subsequent chemotherapy cycles. The aim of the study was to assess antiemetic therapy prescribing and CINV control in the acute phase (24 hours post-chemotherapy) and the delayed phase (days 2–4 post-chemotherapy). Factors influencing CINV control were also determined.MethodsInformation on antiemetic premedication was gathered from patient medical records. Data regarding antiemetic therapy post-discharge and CINV control were in both phases obtained using patient questionnaires. Antiemetic therapy prescribing was compared with internal CINV prevention and control guidelines. Predictive factors for CINV control were evaluated using binary logistic regression.ResultsThere were 62 patients enrolled in the study, out of which 50 (80.6%) received adequate antiemetic premedication. In the acute phase, 46 (74.2%) patients reported well-controlled CINV, whereas 16 (25.8%) reported uncontrolled CINV. None of the patients was prescribed post-discharge antiemetic therapy as per guidelines. In the delayed phase, CINV was more frequent as 39 (62.9%) patients reported well-controlled CINV, whereas uncontrolled CINV was reported in 23 (37.1%) patients. The predictive factors for overall CINV control were prescription of corticosteroids (OR=9.025, p=0.019) and patient age (OR=0.851, p=0.002). The delayed CINV control was dependent on age (OR=0.885, p=0.030) and acute CINV control (OR=17.377, p=0.001).ConclusionsThe majority of the patients were prescribed adequate antiemetic therapy for the acute phase but not for the delayed phase, which may have resulted in more patients experiencing delayed CINV.

show abstract

Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries

Abstract: CINV remains a substantial problem, and country-specific information about CINV can be useful in developing strategies to improve outcomes for patients undergoing chemotherapy.

Cited by 51 publications

References 26 publications

In silico investigation into the interactions between murine 5-HT3 receptor and the principle active compounds of ginger (Zingiber officinale)

In silico investigation into the interactions between murine 5-HT3 receptor and the principle active compounds of ginger (Zingiber officinale)

Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study

Control of chemotherapy-induced nausea and vomiting in patients with gastrointestinal tumours

Contact Info

Product

Resources

About